- 9 hrs ago Sonakshi Sinha, Karisma Kapoor, And Other Divas Flaunt Party Outfits At This Party
- 10 hrs ago On Zeenat Aman's Birthday, The Actress Whose Fashion Was Beyond The Conformist Narrative
- 11 hrs ago Copaiba Oil: Health Benefits, Risks And How To Use
- 11 hrs ago Urvashi Rautela's Perfect Glossy Pout And Pretty Half Updo Hairstyle Are Something You Can't Miss
- News JNU protests: Delhi Police registers FIRs; JNUSU says no action should be taken against protesters
- Movies When Katrina Kaif Left Salman Khan Blushing!
- Sports 2022 FIFA World Cup Qualifiers, India vs Oman: India go down by a solitary goal in Muscat
- Technology 99% of Xiaomi Smartphones Sold In India Are Made In The Country
- Automobiles MotoGP Repsol Honda Team Signs Alex Marquez For 2020 Season: Will Race With Marc Marquez
- Travel Overtourism – Why It Matters, The Destinations Affected And How To Combat It
- Finance Job Creation Growth In India Slowed Down In Last 2 Years: CARE Ratings
- Education JEE Main 2020 Sample Question Paper With Solution For Numerical Value Section
According to a recent study report, a vaccine to protect people against the sexually transmitted infection, chlamydia, has passed the initial safety tests. It is the first of its kind to enter the human trials and more trials have to be done to check how well it works and what dose to give according to the study published in the journal, The Lancet Infectious Diseases  .
As per the study, national screening programmes and antibiotic treatment haven't worked to decrease the incidence rate of chlamydia, and till date no vaccines against it have been tested in clinical trials.
So, the aim of the study was to analyse the safety and immunogenicity, in humans, of a new chlamydia vaccine based on a recombinant protein subunit (CTH522) in a prime-boost immunisation schedule.
What Is Chlamydia?
According to the study, chlamydia is the most common sexually transmitted bacterial infection globally. It occurs when you have unprotected sex, even if there is no penetration. It spreads through semen or vaginal discharge, because the chlamydia bacteria live in semen and vaginal fluid.
If the bacterial infection isn't treated with antibiotics, it can cause serious complications and may even cause infertility. It is estimated that around 70 to 80 per cent of women suffer from chlamydia infection without symptoms. It is more common in women than men  .
Why A Vaccine Is Required For Chlamydia
Experts believe that vaccination could give long-lasting protection. In the trial, researchers compared two different formulations of the vaccine alongside a placebo jab in 35 women. Both the formulations are safe, but one of them is considered very effective.
The vaccine produces a type of immune response that could protect against chlamydia. But, the vaccine will be sent for further trials to test whether it is truly protective or not.
-  Abraham, S., Juel, H. B., Bang, P., Cheeseman, H. M., Dohn, R. B., Cole, T., … Follmann, F. (2019). Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases.
-  Menon, S., Timms, P., Allan, J. A., Alexander, K., Rombauts, L., Horner, P., ... & Huston, W. M. (2015). Human and pathogen factors associated with Chlamydia trachomatis-related infertility in women.Clinical microbiology reviews,28(4), 969-985.